Polycyclic aromatic hydrocarbons (PAHs) are an environmentally ubiquitous class of compounds that are formed during incomplete combustion of organic substances. Several PAHs have been classified as probable human carcinogens ([@b5-ehp-117-552]; [@b53-ehp-117-552]). In the general population, the major source of exposure is tobacco smoke ([@b38-ehp-117-552]), with diet (grilled/smoked foods, cereals, and leafy green vegetables) and exposure to fossil fuel combustion by-products contributing to cumulative exposure ([@b61-ehp-117-552]). Although there is strong evidence for the relationship between PAH exposure and lung, skin, and bladder cancer in humans, it is equivocal as to whether PAH exposure is associated with breast cancer ([@b5-ehp-117-552]; [@b19-ehp-117-552]; [@b53-ehp-117-552]).

PAH--DNA adducts reflect not only PAH exposure but also the body's ability to metabolize these compounds. The formation of these carcinogen--DNA adducts is recognized as a key event in the initiation of carcinogenesis ([@b18-ehp-117-552]; [@b29-ehp-117-552]; [@b64-ehp-117-552]). In the Long Island Breast Cancer Study Project (LIBCSP), a large population-based case--control study, blood levels of PAH--DNA adducts were associated with a modest 29--35% elevation in breast cancer risk among women ([@b18-ehp-117-552]). These findings are consistent with previously conducted, smaller hospital-based studies ([@b37-ehp-117-552], [@b36-ehp-117-552]; [@b48-ehp-117-552]). Animal studies have provided further support for the role of PAHs as mammary carcinogens ([@b8-ehp-117-552]; [@b13-ehp-117-552]). Although a significant association between breast cancer risk and detectable PAH--DNA adducts has been noted, a dose--response relationship was not observed in the LIBCSP. Further stratification by known sources of PAH exposure, such as cigarette smoking or the consumption of PAH-containing foods, did not modify this association ([@b18-ehp-117-552]). These findings are consistent with those from smaller studies ([@b33-ehp-117-552]). The lack of a dose response effect suggests that there may be subgroups of women who are more genetically susceptible to the carcinogenic effects of PAH exposure on breast tissue.

Inherited differences in the metabolism of PAHs, interindividual differences in enzyme expression, and induction may be key determinants in individual breast cancer susceptibility ([@b53-ehp-117-552]). Genetic differences in metabolic activation and detoxification of PAHs have been shown to affect differences in phenotypic biomarkers such as urinary metabolites and are hypothesized to influence cancer risk ([@b6-ehp-117-552]; [@b24-ehp-117-552]; [@b30-ehp-117-552]; [@b35-ehp-117-552]; [@b58-ehp-117-552]; [@b64-ehp-117-552]). Further investigation of these genetic differences in the deactivation of PAH metabolites may contribute to our understanding of the lack of a dose--response relationship and increased understanding of breast cancer risk.

The phase II metabolic super family of GST enzymes is involved in the metabolic activation and deactivation of PAH metabolites, and polymorphisms in these genes lead to specific changes in enzyme function and the capacity to metabolize PAH compounds ([@b27-ehp-117-552]). The *GSTM1* null polymorphism \[GenBank BC036805; [@b42-ehp-117-552]\] results in the absence of isoenzyme (mu) expression and reduced glutathione binding efficiency of PAH epoxides and other genotoxic substrates ([@b25-ehp-117-552]). The *GSTP* 1le105Val polymorphism \[*GSTP1*; Unigene Hs.523836 ([@b43-ehp-117-552])\] is associated with reduced isoenzyme (pi) expression and a reduced capacity to inactivate carcinogens, including the diol epoxides created during phase I metabolism of PAHs ([@b10-ehp-117-552]; [@b44-ehp-117-552]; [@b51-ehp-117-552]; [@b62-ehp-117-552]). The *GSTT1* null polymorphism (Genbank X79389) results in the absence of (theta) isoenzyme ([@b25-ehp-117-552]), but the role of this polymorphism in relation to PAH metabolism is uncertain ([@b44-ehp-117-552]). On the one hand, the theta isoenzyme is thought to activate alkylating agents, such as nitrosamines present in tobacco smoke ([@b27-ehp-117-552]; [@b44-ehp-117-552]); on the other hand, in human erythrocytes, the theta isoenzyme binds reactive conjugates to glutathione, inhibiting genotoxic damage to DNA ([@b45-ehp-117-552]). GSTs conjugate PAH diol epoxides into water-soluble products, and GST enzymes also protect against products of oxidative stress ([@b40-ehp-117-552]). *GSTA1* (Unigene Hs. 446309) is thought to decrease reactive oxygen species and, via an increase in antioxidant levels, to also play an active role in PAH metabolism ([@b1-ehp-117-552]; [@b11-ehp-117-552]; [@b34-ehp-117-552]). For *GSTA1*, two alleles, *hGSTA1\*A* and *hGSTA1\*B*, differ in three linked base changes in the 5′ promoter region of the gene: T→G at nucleotide 567, C→T at nucleotide 69, and G→A at nucleotide 52 ([@b12-ehp-117-552], [@b9-ehp-117-552]). These substitutions result in differential expression ([@b9-ehp-117-552]), with lower transcriptional activation with *GSTA1\*B* (variant) than with *GSTA1\*A* (common) alleles. It has been demonstrated by our group that the variant *GSTA1\*B*/*B* genotype is associated with higher risk of breast cancer among smokers compared with nonsmokers with the *A*/*A\** genotype ([@b1-ehp-117-552]).

Only one breast cancer study ([@b50-ehp-117-552]) has reported on a potential interaction between *GSTM1* null genotype and PAH--DNA adducts. However, the sample size was small (\< 100 cases), yielding unstable effect estimates and prohibiting exploration of more than one single nucleotide polymorphism from among the many that contribute to this complex cascade of activation and detoxification. Investigating whether genetically determined differences in multiple *GST* genotypes modify the association between breast cancer risk and PAH exposure may improve our ability to identify women who are susceptible to the carcinogenic effects of PAHs on breast tissue.

The goal of our present analysis was to investigate whether multiple *GST* polymorphisms modified the relationship between PAH exposure and breast cancer, using the lymphocyte PAH--DNA adduct biomarker as our primary exposure measure of interest using a large, population-based sample of cases and controls from the LIBCSP. We also evaluated the interaction between *GST* polymorphisms and smoking status, because smoking behavior was previously identified as the strongest predictor of detectable PAH--DNA adducts ([@b52-ehp-117-552]). Finally, we investigated the joint effects of smoking status and *GST* polymorphisms on detectable PAH--DNA adducts among control women.

Methods
=======

Study population
----------------

The population-based sample of cases and controls from the LIBCSP has been described previously ([@b17-ehp-117-552]). Briefly, cases were defined as English-speaking adult women newly diagnosed with breast cancer residing in Nassau County or Suffolk County in Long Island, New York. Population-based controls were identified through random-digit dialing for women \< 65 years of age, and by Health Care Finance rosters for women ≥ 65 years of age within the same counties, and frequency matched them (by 5-year age groups) to cases. Participants were between 20 and 98 years of age; 94% were white, 4% were black, and 2% other races/ethnicities. The study protocol was approved by the institutional review boards of the collaborating institutions, and written informed consent was obtained from the LIBCSP participants.

Data collection
---------------

Respondents to the case--control interview included 1,508 cases and 1,556 controls ([@b17-ehp-117-552]). The 2-hr in-person structured interview collected data on history of cigarette smoking (current, past), exposure to environmental tobacco smoke in the residential home throughout the life course ([@b16-ehp-117-552]), and other characteristics potentially relevant to breast cancer risk. Blood samples were obtained from 73% of cases and 73% of controls ([@b18-ehp-117-552]).

Laboratory assays
-----------------

We processed the blood samples collected by [@b18-ehp-117-552], isolated the DNA and completed genotyping for *GSTT1* and *GSTM1* as previously described ([@b56-ehp-117-552]), by a multiplex polymerase chain reaction method as previously described ([@b4-ehp-117-552]). Genotyping for *GSTP1* (Ile105Val; rs1695) ([@b56-ehp-117-552]) and *GSTA1* ([@b1-ehp-117-552]) was completed as previously described by matrix-assisted laser desorption/ionization time-of-flight assay ([@b14-ehp-117-552]). We included positive and negative controls in each batch, and a random 10% repeated sampling yielded a 97% concordance. Genotype distributions of *GSTA1* (*p* = 0.81) and *GSTP1* (*p* = 0.38) were in Hardy-Weinberg equilibrium among controls. The number of cases and controls, respectively, for whom genotyping was successful varied with genotype (*n* = 1,041 and 1,090 for *GSTA1*, 983 and 1,016 for *GSTT1*, 975 and 1,001 for *GSTM1*, and 1,027 and 1,069 for *GSTP1*). Missing genotype data were primarily due to insufficient DNA ([@b1-ehp-117-552]; [@b56-ehp-117-552]).

PAH--DNA adducts were measured in peripheral mononuclear cell DNA using competitive enzyme-linked immunosorbent assay as previously described ([@b20-ehp-117-552]). PAH--DNA adduct measurements were available for 873 cases and 941 controls who donated sufficient blood volume for the assay, as described previously ([@b18-ehp-117-552]).

Statistical methods
-------------------

We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression using SAS version 9.0 (SAS Institute Inc., Cary, NC). All models were adjusted for age at reference (date of diagnosis for cases and date of identification for controls), the frequency-matching factor. Covariates considered as potential confounders included race, family history of breast cancer, parity, age at menarche, age at first pregnancy, menopausal status, lifetime alcohol intake, education, and smoking status. We considered a covariate a confounder and included it in the models if it changed the ORs by more than 10% ([@b32-ehp-117-552]); however, adjustment by these potential confounders did not appreciably change the ORs, and therefore only the age-adjusted estimates are shown.

For our first set of analyses, our goal was to determine whether breast cancer risk is associated with the *GST* polymorphisms and whether they interact with PAH exposures, either alone or jointly, to affect breast cancer risk. We previously reported that the ORs for the association between breast cancer and individual *GST* genotypes were not substantially elevated ([@b1-ehp-117-552]; [@b56-ehp-117-552]), although risk was elevated when we considered multiple *GST*s ([@b1-ehp-117-552]; [@b56-ehp-117-552]). Here, we focus primarily on the analyses that examine the interaction of *GST*s with adducts and smoking, using the following methods.

We estimated the ORs for breast cancer in relation to potential interactions between various PAH measures and the *GST* polymorphisms, *a*) considering each polymorphism separately ([Table 1](#t1-ehp-117-552){ref-type="table"}), and (*b*) by grouping individuals based on the number of variant alleles for any of the four *GST* polymorphisms considered ([Tables 2](#t2-ehp-117-552){ref-type="table"} and [3](#t3-ehp-117-552){ref-type="table"}). For this group of analyses, the reference group included women with *GSTT1* present, *GSTM1* present, *GSTP1* common (*AG* or *GG*), or *GSTA1* common (*A*/*A\**) genotypes. Using this approach, we explored the effect of even a single at-risk genotype, among those who carried common alleles for the other *GST*s considered. We chose to group the genes this way based on experimental evidence indicating reduced or no enzyme activity for the variant and null genotypes. In terms of metabolism, the *GSTP1* valine genotype is thought to be associated with lower glutathione *S*-transferase pi enzyme activity compared with the *GSTP1* isoleucine genotype, which plays a key role in the detoxification of benzo\[*a*\]pyrene diol epoxide, a major carcinogen present in tobacco smoke ([@b15-ehp-117-552]; [@b27-ehp-117-552]; [@b41-ehp-117-552]). To explore these potential gene--PAH interactions, we developed separate models for women based on the presence or absence of the PAH exposure measure \[PAH--DNA adducts (detectable/not detectable); self-reported cigarette smoking status (ever/never, or current/past/never)\] or pack years of smoking history (\< 15 years, 15--30 years, \> 30 years). We also developed models for all women that included multiplicative interaction terms ([@b32-ehp-117-552]); gene--environment interactions were formally assessed by examining departures from multiplicity by comparing models with and without the interaction term using the likelihood ratio test (LRT) ([@b32-ehp-117-552]). In addition, we investigated potential interactions on the additive scale ([@b32-ehp-117-552]) using joint indicator terms for genotype only, for PAH measure only, and for both genotype and PAH measure ([Tables 3](#t3-ehp-117-552){ref-type="table"} and [4](#t4-ehp-117-552){ref-type="table"}). Interaction contrast ratios (ICRs) and their 95% CIs were calculated to measure the relative excess risk due to interaction ([@b3-ehp-117-552]; [@b46-ehp-117-552]). We also considered other categorizations of smoking exposure status that incorporated information collected by the questionnaire on environmental tobacco smoke ([@b16-ehp-117-552]), but the cell sizes were too small to yield meaningful results, so we do not show these data.

For our second set of analyses, our goal was to determine the association between PAH--DNA adducts and the *GST* variant alleles among control women only. We used unconditional logistic regression with detectable adducts as the dependent variable, and *GST*s as the independent variable, controlling for age at reference and season of blood draw ([Table 4](#t4-ehp-117-552){ref-type="table"}). We also investigated the main effect of each genotype or number of variant alleles on the outcome of detectable PAH--DNA adducts in a multivariate model adjusted for age, smoking status, and season of blood draw. In a previous study ([@b52-ehp-117-552]), we found that cigarette smoking was a significant predictor of detectable PAH--DNA adducts among this population-based sample; thus, we also explored whether the *GST* genotypes modified the association between smoking status and detectable adducts. We also considered potential interactions with cigarette smoke because of its link to our biomarker, although we recognize that other PAH sources and other constituents of tobacco smoke could potentially interact with *GST* polymorphisms to affect risk; however, these other constituents of tobacco smoke have not been linked to breast cancer risk in a human study.

Results
=======

Individual GSTs, PAHs, and breast cancer risk
---------------------------------------------

As shown in [Tables 1](#t1-ehp-117-552){ref-type="table"} and [2](#t2-ehp-117-552){ref-type="table"}, we did not observe substantial effect modification, on a multiplicative or additive scale, by any of the individual genotypes on the associations between breast cancer risk and PAH exposure (PAH--DNA adducts or cigarette smoking).

Multiple GSTs and breast cancer risk
------------------------------------

The ORs for the association between breast cancer risk and multiple *GST* variant alleles were 1.10 (95% CI, 0.77--1.57) for three or more variants, 0.76 (95% CI, 0.56--1.03) for two variants, and 0.80 (95% CI, 0.59--1.08) for one variant. When we considered the combined effects of *GSTM1*, *-P1*, *-T1*, and -*A1* variants that are coded based on their PAH-related biologic activity (rather than for their isothiocyanate-related activity), we did not find a significant association between the number of variant *GST* alleles and breast cancer risk.

Multiple GSTs, PAHs, and breast cancer risk
-------------------------------------------

[Table 3](#t3-ehp-117-552){ref-type="table"} illustrates the potential joint effects of PAH--DNA adducts and the number of *GST* polymorphisms (one, two, or three or more variants) and breast cancer risk. We observed a 56% increase in risk (OR = 1.56; 95% CI, 1.13--2.16) among women with detectable adducts and three or more *GST* variants \[*GSTT1* null variant, *GSTM1* null variant, *GSTP1 AG*/*GG* genotype, *GSTA1* common (*A\**/*B\** or *B\**/*B\**) genotypes\] compared with those with all common genotypes and no detectable PAH--DNA adducts. The corresponding OR for three or more variants and no detectable adducts was 0.93 (95% CI, 0.56--1.56). Women with one variant allele and no detectable adducts had a 44% reduced risk of breast cancer compared with women with all common alleles and no detectable adducts (OR, 0.56; 95% CI, 0.40--0.77); the corresponding OR for detectable adducts was not significant (OR, 0.97; 95% CI, 0.78--1.20; [Table 3](#t3-ehp-117-552){ref-type="table"}).

As shown in [Table 4](#t4-ehp-117-552){ref-type="table"}, the ORs for the association between breast cancer risk and the number of *GST* variant alleles varied little with smoking status, and results for interaction on either a multiplicative or additive scale were not statistically significant. For example, the OR associated with three or more *GST* variants was 1.18 among ever smokers (95% CI, 0.82--1.69) but was 1.44 among never smokers (95% CI, 0.97--2.14). Results for the interaction between multiple *GST* variants and pack-years of smoking (data not shown) are similar to those shown in [Table 4](#t4-ehp-117-552){ref-type="table"}.

When we categorized ever smokers by whether they were current or past smokers, the OR for the association between breast cancer risk and three or more *GST* variants was 0.62 (95% CI, 0.27--1.43) among current smokers, and 1.66 (95% CI, 0.93--2.97) among past smokers, compared with never smokers with all four common alleles. However, the category sizes upon which these estimates are based were small (data not shown), and the *p*-value for the interaction on a multiplicative scale was 0.31.

GSTs, smoking, and PAH--DNA adducts among control women
-------------------------------------------------------

We did not observe a significant association between any single *GSTT1*, *GSTM1*, *GSTP1*, or *GSTA1* polymorphism and detectable PAH--DNA adducts among the control women (*GSTT1*: OR, 1.09; 95% CI, 0.77--1.56; *GSTM1*: OR, 0.93; 95% CI, 0.69--1.25; *GSTP1*: OR, 0.95; 95% CI, 0.72--1.27; *GSTA1*: OR, 1.15; 95% CI, 0.86--1.53) or the number of variant genotypes and detectable PAH--DNA adducts (one variant compared with all common alleles: OR, 1.60; 95% CI, 0.92--2.79; two variants compared with all common alleles: OR, 1.35; 95% CI, 0.77--2.36; three or more variants compared with all common alleles: OR, 1.45; 95% CI, 0.75--2.82). [Table 5](#t5-ehp-117-552){ref-type="table"} shows the association between *GST* polymorphisms and PAH--DNA adducts among control women stratified by smoking status. Women who ever smoked and had the *GSTM1* present genotype had a 35% reduced odds (OR, 0.65; 95% CI, 0.45--0.93) of having detectable PAH--DNA adducts compared with never smokers with the same genotype. We noted similar results forever smokers with the *GSTM1* null genotype compared with never smokers with the *GSTM1* common genotype (OR, 0.64; 95% CI, 0.43--0.93). Ever smokers with the *GSTT1* present genotype had a 27% reduced odds of PAH--DNA adducts (OR, 0.73; 95% CI, 0.53--0.99) compared with never smokers with the same genotype. Ever smokers with the common *GSTA1* genotype had a reduced odds of PAH--DNA adducts compared with never smokers with the same genotype (OR, 0.67; 95% CI, 0.47--0.96; [Table 5](#t5-ehp-117-552){ref-type="table"}). We found no evidence of effect modification between any of the individual genotypes and smoking status on PAH--DNA adduct status on the multiplicative scale (LRT *p*-values: *GSTT1*, 0.20; *GSTM1*, 0.75; *GSTP1*, 0.15; *GSTA1*, 0.40) or on the additive scale. We did not find statistical evidence between number of variant alleles and smoking status on the odds of developing detectable PAH--DNA adducts on the additive scale (one-variant allele: ICR, 0.28; 95% CI, --0.39 to 0.45; two-variant alleles: ICR, --0.091; 95% CI, --0.57 to 0.38; three or more variant alleles: ICR, 0.177; 95% CI, --0.23 to 0.59) or on the multiplicative scale (*p*-value from the LRT = 0.13). When considering the number of adducts as a continuous outcome (data not shown), we found no evidence of a main effect of the individual genotypes on the number of adducts in an age-adjusted model (*GSTT1 p* = 0.86, *GSTM1 p* = 0.54, *GSTP1 p* = 0.91, *GSTA1 p* = 0.86).

Discussion
==========

To the best of our knowledge, this is the first epidemiologic investigation of breast cancer to consider the joint effects of four *GST* polymorphisms and several measures of PAH exposure, including a PAH--DNA adduct biomarker. Despite the biologic plausibility of our hypothesis, we found no strong evidence for an interaction between the number of variant *GST* alleles with various measures of PAH exposure (including ever/never smoking status, pack-years of smoking, or detected PAH--DNA adducts) and breast cancer risk, nor did we find an association among the control women between number of variant *GST* polymorphisms and the outcome of detectable PAH--DNA adducts. We found some evidence for a reduced risk of detectable adducts among control women who were ever smokers regardless of whether they had the *GSTM1* deletion polymorphism or the present genotype ([Table 5](#t5-ehp-117-552){ref-type="table"}). We also report for the first time that among controls with the *A\**/*A\* GSTA1* genotype, ever smokers had lower odds of having detectable PAH--DNA adducts than did never smokers with the same genotype (OR, 0.62; 95% CI, 0.41--0.92).

GST polymorphisms and breast cancer risk
----------------------------------------

A few previous studies ([@b31-ehp-117-552]; [@b59-ehp-117-552]) including our own have found that individual polymorphisms in *GSTA1* ([@b1-ehp-117-552]), *GSTM1* null ([@b31-ehp-117-552]; [@b54-ehp-117-552]), and *GSTT1* null ([@b59-ehp-117-552]) and *GSTP1* (heterozygote or homozygote valine) ([@b31-ehp-117-552]) are modestly associated with breast cancer, although others have reported no association with *GSTT1* ([@b21-ehp-117-552]; [@b31-ehp-117-552]; [@b60-ehp-117-552]), *GSTP1* ([@b60-ehp-117-552]), or *GSTM1* ([@b2-ehp-117-552]; [@b21-ehp-117-552]; [@b60-ehp-117-552]). Effects of multiple combinations of *GST* polymorphisms on breast cancer risk have previously been conducted in smaller studies, with conflicting findings ([@b31-ehp-117-552]; [@b56-ehp-117-552]; [@b59-ehp-117-552]; [@b60-ehp-117-552]). Combined effect of all three *GSTT1*, *GSTM1*, and *GSTP1* variants have been reported to have greater than a 3-fold increase in breast cancer risk compared with women with the common genotype for all three polymorphisms ([@b31-ehp-117-552]; [@b56-ehp-117-552]). In this analysis, in which we considered the combined effects of the *GSTT1*, *-M1*, *-P1*, and -*A1* variants that are coded based on their PAH-related biologic activity (rather than for their isothiocyanate-related activity), we did not find a significant association between the number of variant *GST* alleles and breast cancer risk.

GST polymorphisms, PAHs, and breast cancer
------------------------------------------

Previous studies have differed on whether *GST* polymorphisms modify the association between cigarette smoking and breast cancer risk ([@b39-ehp-117-552]; [@b57-ehp-117-552]; [@b59-ehp-117-552]; [@b60-ehp-117-552]; [@b65-ehp-117-552]). Smaller studies have reported that smoking did not modify associations between *GSTT1* ([@b60-ehp-117-552]), *GSTM1* ([@b59-ehp-117-552]; [@b60-ehp-117-552]), or *GSTP1* polymorphisms ([@b60-ehp-117-552]) and breast cancer, whereas former smokers with *GSTT1* null were found to have an increased risk of breast cancer compared with never smokers with *GSTT1* present ([@b59-ehp-117-552]). For example, one recent breast cancer meta-analysis reported no interaction between individual *GST* polymorphisms and smoking, whereas another meta-analysis reported positive associations between breast cancer risk and *GSTT1* present and *GSTM1* null genotypes among smokers ([@b57-ehp-117-552]; [@b60-ehp-117-552]). In contrast, we observed an increased risk of breast cancer with three or more variant *GST* alleles in a previous analysis ([@b56-ehp-117-552]), but no increased risk with number of variant alleles as defined by low PAH-metabolizing activity, and no evidence of gene--environment interaction with PAH exposure. Our present findings are unique in that we investigated four *GST* polymorphisms simultaneously in a single large study.

To the best of our knowledge, this is the first study to examine the interaction between PAH--DNA adducts and individual/combined effects of *GSTA1*, *GSTM1*, *GSTP1*, and *GSTT1* genotypes on breast cancer risk. We found no pronounced adverse effect for the genotype--PAH exposure interaction, regardless of the PAH measure. Given that the genetic polymorphisms we examined are known to be functionally associated with deactivation of the active intermediates of PAHs, our findings are not easily interpreted. It is possible that the PAH--DNA adduct biomarker effect estimates already reflect any effects associated with metabolic variation; however, if this were true, then any apparent interaction between PAHs and *GST*s should have been evident when examining the joint effects with smoking. We found a reduction in risk among women with at least one variant allele and no detectable adducts, but we did not find a similar reduction among these same women in relation to no smoking. Thus, we do not report evidence that PAHs interacted with these polymorphisms to further increase risk.

We acknowledge that expression of GSTs can be modulated by a variety of factors, including diet. There is extensive literature on animal studies demonstrating an interaction between isothiocyanates and PAHs on cancer risk, and the induction of phase II enzymes by isothiocyanates ([@b26-ehp-117-552], [@b28-ehp-117-552]). The interaction between GSTs and isothiocyanates does not appear to interact to affect breast cancer risk in humans or the variations in the urinary metabolites of isothiocyanates in our data ([@b55-ehp-117-552], [@b56-ehp-117-552]). Whether cruciferous vegetable intake would further interact with PAHs and GSTs to affect breast cancer risk is unclear. Unfortunately, this study was underpowered to explore such three way interactions despite a large sample size. Nevertheless, it may be theoretically possible that breast cancer risk is influenced by a potential three-way interaction of PAH--DNA adducts, *GST* polymorphisms, and cruciferous vegetable intake, although our current available data do not support this hypothesis ([@b55-ehp-117-552], [@b56-ehp-117-552]).

GST polymorphisms, smoking, and PAH--DNA adducts among control women
--------------------------------------------------------------------

We considered the PAH--DNA adduct outcome as both a continuous and a dichotomous variable (detected/not detected), although the latter may be more informative given the lack of a dose--response relationship between adducts and breast cancer risk ([@b20-ehp-117-552]). In our analyses among control women, individual *GSTT1*, *GSTM1*, *GSTP1*, and *GSTA1* genotypes were not associated with detectable PAH--DNA adducts, nor was the number of variant *GST* alleles. Even after stratification on smoking, the number of variant *GST* alleles was not associated with detectable PAH--DNA adducts; however, ever smokers with either the *GSTM1* null or *GSTM1* present genotype had a reduced risk of detectable PAH--DNA adducts ([Table 5](#t5-ehp-117-552){ref-type="table"}). We observed a similar finding within the strata of ever smokers and the *GSTP1* common genotype compared with never smokers with the common genotype. Our results are the first published findings regarding *GSTA1* polymorphisms and PAH--DNA adducts. Our findings related to polymorphisms in *GSTM1* and PAH--DNA adduct formation are in contrast with one study ([@b49-ehp-117-552]), while being consistent with others that report no significant difference in detectable PAH--DNA adducts based on *GSTM1* status ([@b23-ehp-117-552]; [@b47-ehp-117-552]; [@b63-ehp-117-552]). However, the LIBCSP results reported here are based upon a much larger sample size than previous analyses, which yields more stable effect estimates. Additionally, we used different methods to measure the PAH--DNA adducts in the various studies, possibly influencing the results.

Methodological considerations
-----------------------------

In an epidemiologic study, the use of a biomarker of exposure, such as PAH--DNA adducts, is considered superior because exposure assessment is not based on self-report, eliminating concerns for recall bias. Reliability in the measurement of genotype and adducts was high. Measurement error was possible, although unlikely with genotyping and analysis of adducts; however, because the laboratory was blinded to status of samples, any measurement error in measuring genotype and of PAH--DNA adduct status was independent of case--control status. Therefore, any resulting bias would have been nondifferential.

Our study power was limited when we examined interactions within subgroups of women, such as those with PAH--DNA adducts. However, the LIBCSP is the largest study conducted to date with information on PAH--DNA adducts with which to evaluate these associations, and thus our study power was better than that of previously reported studies.

We selected the *GST* polymorphisms because of their role in phase II metabolism, specifically metabolism of PAH-reactive intermediates. Because PAH--DNA adducts may be related to inherited differences in the metabolism of PAHs, this pathway was hypothesized to be important in individual breast cancer susceptibility. *GSTP1* and *GSTM1* have been shown to have a role in detoxification of PAH carcinogenic intermediates produced by cytochrome P450 in phase I metabolism ([@b7-ehp-117-552]). *GSTT1* and *GSTA1* have also been implicated in the metabolism of PAH intermediates ([@b22-ehp-117-552]; [@b25-ehp-117-552]; [@b34-ehp-117-552]).

Conclusion
==========

Our previous analyses have shown that breast cancer risk was modestly elevated in relation to PAH--DNA adducts ([@b20-ehp-117-552], [@b18-ehp-117-552]), among certain subgroups of smokers ([@b16-ehp-117-552]), and among women with multiple variant alleles in *GST* genes ([@b56-ehp-117-552]). In this analysis, however, we did not find strong evidence for further elevation of breast cancer risk, either on a multiplicative or on an additive scale, when we considered the joint effect of multiple GSTs and PAHs (cigarette smoking or PAH--DNA adducts), despite the biologic plausibility of such an interaction. These findings are based upon the largest population-based study of breast cancer conducted to date with a biomarker of PAH exposure. Further study may be warranted incorporating other biologic measures of PAH metabolism.
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###### 

Age-adjusted ORs (95% CIs) for the individual *GST* genotypes on the associations between smoking status and breast cancer risk.

  Genotype                      Smoking status   Cases (*n* )   Controls (*n* )   OR (95% CI)         *p*-Value[a](#tfn2-ehp-117-552){ref-type="table-fn"}
  ----------------------------- ---------------- -------------- ----------------- ------------------- ------------------------------------------------------
  *GSTT1*                                                                                             
   Present                      Never            351            341               1.0                 0.27
                                Ever             423            454               0.94 (0.80--1.11)   
   Null                         Never            97             112               0.97 (0.66--1.16)   
                                Ever             112            109               1.04 (0.78--1.37)   
                                                                                                      
  *GSTM1*                                                                                             
   Present                      Never            227            247               1.0                 0.62
                                Ever             278            300               0.98 (0.81--1.19)   
   Null                         Never            218            201               1.14 (0.92--1.42)   
                                Ever             252            253               1.06 (0.86--1.29)   
                                                                                                      
  *GSTP1*                                                                                             
   *AA* (common)                Never            235            242               1.0                 0.86
                                Ever             275            309               0.91 (0.75--1.10)   
   *AG* or *GG*                 Never            239            234               1.04 (0.85--1.28)   
                                Ever             278            284               1.01 (0.83--1.22)   
                                                                                                      
  *GSTA1*                                                                                             
   *A\**/*A\** (common)         Never            145            168               1.0                 0.60
                                Ever             199            218               0.96 (0.77--1.20)   
   *A\**/*B\** or *B\**/*B\**   Never            335            328               1.06 (0.88--1.28)   
                                Ever             362            376               1.02 (0.85--1.22)   

Common alleles: *GSTT1* present, *GSTM1* present, *GSTP1* (*AA*), *GSTA1* (*A\**/*A\**). Variant alleles: *GSTT1* null, *GSTM1* null, *GSTP1* (*AG* or *GG*), *GSTA1* (*A\**/*B\** or *B\**/*B\**).

From likelihood ratio test.

###### 

Age-adjusted ORs (95% CIs) for the individual *GST* genotypes on the associations between PAH--DNA adducts and breast cancer risk.

  Genotype                      PAH--DNA adducts   Cases (*n*)   Controls (*n*)   OR (95% CI)         *p*-Value[a](#tfn4-ehp-117-552){ref-type="table-fn"}
  ----------------------------- ------------------ ------------- ---------------- ------------------- ------------------------------------------------------
  *GSTT1*                                                                                             
   Present                      −                  165           204              1.0                 0.22
                                \+                 463           474              1.01 (0.87--1.19)   
   Null                         −                  40            61               0.68 (0.45--1.03)   
                                \+                 134           124              1.14 (0.87--1.48)   
                                                                                                      
  *GSTM*1                                                                                             
   Present                      −                  104           146              1.0                 0.75
                                \+                 301           320              0.99 (0.82--1.19)   
   Null                         −                  100           114              0.93 (0.70--1.23)   
                                \+                 293           274              1.13 (0.93--1.37)   
                                                                                                      
  *GSTP1*                                                                                             
   *AA* (common)                −                  107           133              1.0                 0.77
                                \+                 320           293              0.94 (0.78--1.13)   
   *AG* or *GG*                 −                  106           153              0.83 (0.63--1.09)   
                                \+                 304           333              1.15 (0.95--1.38)   
                                                                                                      
  *GSTA1*                                                                                             
   *A\*/A\**                    −                  75            111              1.0                 0.53
                                \+                 211           223              0.97 (0.78--1.20)   
   *A\**/*B\** or *B\**/*B\**   −                  145           179              0.83 (0.65--1.05)   
                                \+                 416           413              1.03 (0.86--1.22)   

Common alleles: *GSTT1* present, *GSTM1* present, *GSTP1* (*AA*), *GSTA1* (*A\**/*A\**). Variant alleles: *GSTT1* null, *GSTM1* null, *GSTP1* (*AG* or *GG*), *GSTA1* (*A\**/*B\** or *B\**/*B\**). Symbols: +, PAH--DNA adducts detected; --, PAH--DNA adducts not detected.

From likelihood ratio test.

###### 

Age-adjusted ORs (95% CIs) for the effects of number of variant genotypes, PAH--DNA adducts, and risk of breast cancer.

  No. of variants   PAH--DNA adduct status   Cases (*n*)   Controls (*n*)   OR (95% CI)           *p*-Value[a](#tfn6-ehp-117-552){ref-type="table-fn"}   ICR (95% CI)
  ----------------- ------------------------ ------------- ---------------- --------------------- ------------------------------------------------------ ----------------------
  Four common       −                        28            20               1.00                                                                         
                    \+                       72            68               1.01 (0.71 to 1.43)                                                          Referent
  One variant       −                        64            112              0.56 (0.40 to 0.77)   0.05                                                   
                    \+                       215           219              0.97 (0.78 to 1.20)                                                          0.60 (0.23 to 0.97)
  Two variants      −                        74            93               0.78 (0.56 to 1.07)   0.18                                                   
                    \+                       183           222              0.82 (0.66 to 1.03)                                                          0.36 (−0.12 to 0.84)
  Three variants    −                        29            31               0.93 (0.56 to 1.56)   0.43                                                   
                    \+                       105           66               1.56 (1.13 to 2.16)                                                          0.75 (0.20 to 1.30)

Common alleles: *GSTT1* present, *GSTM1* present, *GSTP1* (*AA*), *GSTA1* (*A\**/*A\**). Variant alleles: *GSTT1* null, *GSTM1* null, *GSTP1* (*AG* or *GG*), *GSTA1* (*A\**/*B\** or *B\**/*B\**). Symbols: +, PAH--DNA adducts detected; --, PAH--DNA adducts not detected.

From likelihood ratio test.

###### 

Age-adjusted ORs (95% CIs) for the effect of number of variant genotypes, smoking status, and risk of breast cancer.

  No. of variants          Smoking status   Cases (*n*)   Controls (*n*)   Total   OR (95% CI)           *p*-Value[a](#tfn8-ehp-117-552){ref-type="table-fn"}   ICR (95% CI)
  ------------------------ ---------------- ------------- ---------------- ------- --------------------- ------------------------------------------------------ ----------------------
  Four common              Never            58            39               97      1.0                                                                          
                           Ever             65            66               131     0.98 (0.67 to 1.43)   0.24                                                   Referent
  One variant              Never            162           177              339     0.96 (0.73 to 1.25)                                                          
                           Ever             188           204              392     0.91 (0.71 to 1.18)   0.66                                                   0.30 (−0.13 to 0.72)
  Two variants             Never            139           164              303     0.89 (0.68 to 1.18)                                                          
                           Ever             179           204              383     0.88 (0.68 to 1.14)   0.52                                                   0.32 (−0.10 to 0.73)
  Three or more variants   Never            70            51               121     1.44 (0.97 to 2.14)                                                          
                           Ever             82            68               150     1.18 (0.82 to 1.69)   0.62                                                   0.15 (−0.47 to 0.77)

Common alleles: *GSTT1* present, *GSTM1* present, *GSTP1* (*AA*), *GSTA1* (*A\**/*A\**). Variant alleles: *GSTT1* null, *GSTM1* null, *GSTP1* (*AG* or *GG*), *GSTA1* (*A\**/*B\** or *B\**/*B\**).

From likelihood ratio test.

###### 

Age-adjusted ORs (95% CIs) for the joint effect of *GST* polymorphisms and smoking on the outcome of detectable PAH--DNA adducts among control women.

                                 Smoking status   Adducts not detected   Adducts present   OR (95% CI)           *p*-Value[a](#tfn10-ehp-117-552){ref-type="table-fn"}   ICR (95% CI)
  ------------------------------ ---------------- ---------------------- ----------------- --------------------- ------------------------------------------------------- -------------------------
  Genotype                                                                                                                                                               
   *GSTT1*                                                                                                                                                               
    Present                      Never            99                     197               1.0                   0.20                                                    (−0.37 ((−1.04 to 0.31)
                                 Ever             105                    277               0.73 (0.53 to 0.99)                                                           
    Null                         Never            37                     60                1.18 (0.74 to 1.87)                                                           
                                 Ever             24                     64                0.72 (0.43 to 1.20)                                                           
   *GSTM1*                                                                                                                                                               
    Present                      Never            78                     140               1.0                   0.76                                                    0.10 (−0.26 to 0.46)
                                 Ever             68                     180               0.65 (0.45 to 0.93)                                                           
    Null                         Never            56                     115               0.85 (0.57 to 1.26)                                                           
                                 Ever             58                     159               0.64 (0.43 to 0.93)                                                           
   *GSTP1*                                                                                                                                                               
    *AA* (common)                Never            73                     143               1.0                   0.18                                                    (−0.28 ((−1.10 to 0.62)
                                 Ever             80                     190               0.96 (0.69 to 1.34)                                                           
    *AG* or *GG*                 Never            75                     125               1.29 (0.88 to 1.91)                                                           
                                 Ever             58                     168               1.05 (0.72 to 1.52)                                                           
   *GSTA1*                                                                                                                                                               
    *A\**/*A\** (common)         Never            97                     180               1.0                   0.41                                                    (−0.17 ((−0.96 to 0.89)
                                 Ever             82                     233               0.67 (0.47 to 0.96)                                                           
    *A\**/*B\** or *B\**/*B\**   Never            54                     97                1.07 (0.71 to 1.62)                                                           
                                 Ever             57                     126               0.85 (0.57 to 1.26)                                                           
                                                                                                                                                                         
  No. of variants                                                                                                                                                        
   Four common                   Never            9                      24                1.0                   0.13                                                    Referent
                                 Ever             11                     44                0.54 (0.26 to 1.15)                                                           
   One variant                   Never            59                     97                1.26 (0.78 to 2.03)                                                           
                                 Ever             53                     122               0.88 (0.55 to 1.42)                                                           0.28 ((−0.39 to 0.45)
   Two variants                  Never            48                     96                1.06 (0.65 to 1.75)                                                           
                                 Ever             45                     126               0.74 (0.45 to 1.21)                                                           (−0.09 ((−0.57 to 0.38)
   Three variants                Never            16                     27                1.15 (0.56 to 2.35)                                                           
                                 Ever             15                     39                0.79 (0.39 to 1.58)                                                           0.18 ((−0.23 to 0.59)

We adjusted data for age at reference and for season of blood draw. Common alleles: *GSTT1* present, *GSTM1* present, *GSTP1* (*AA*), *GSTA1* (*A\**/*A\**). Variant alleles: *GSTT1* null, *GSTM1* null, *GSTP1* (*AG* or *GG*), *GSTA1* (*A\**/*B\** or *B\**/*B\**).

From likelihood ratio test.
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